NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»01/07/2009 [Company watch]
Bayer Launches New Anti-Clotting Drug in China

Bayer Healthcare has launched its new anti-clotting drug Xarelto (rivaroxaban) in China following SFDA approval.

Bayer Healthcare has launched its new anti-clotting drug Xarelto (rivaroxaban) in China following SFDA approval. As Liam Condon, Managing Director of Bayer HealthCare China said last week at ChinaBio® Partnering Forum, the fact that Xarelto was approved in China before the US shows Bayer’s commitment to bringing innovative drugs to China simultaneously with other major world markets. Xarelto is an oral medication, taken once daily, that was approved for the relatively narrow indication of preventing deep vein thrombosis in patients who undergo knee or hip replacement surgery. Xarelto works by inhibiting the enzyme known as factor Xa. Xa helps thrombin and fibrin fibers combine to form clots. As such, Xarelto’s mechanism is different from the blood thinners that are currently on the market. In tests, Xarelto reduced the incidence of clots in this patient population by 70%, a significant improvement over the 49% reduction of the now-standard enoxaparin. The side effect of bleeding was comparable in the two drugs. Over time, Bayer is expected to seek expanded indications for the drug. Although Xarelto is approved for use in Europe, the FDA in the US has asked for additional information on the drug, though the request will not require Bayer to perform additional tests. The FDA advisory committee recommended approval of the drug. With additional indications, Xarelto is widely expected to become a blockbuster drug, ultimately generating revenues of more than $6 billion a year. Bayer and Johnson & Johnson (JNJ) developed Xarelto jointly, though Bayer has the right to market the drug outside the US.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.